Antibody therapy in acute myeloid leukemia: current status and future directions.
Monoclonal antibodies have become an important modality for cancer therapy. The genetically engineered, humanized anti-CD33 antibody HuM195 has demonstrated modest activity against overt relapsed acute myeloid leukemia (AML) and more substantial activity against minimal residual disease in acute promyelocytic leukemia. Radioimmunotherpay with beta-particle-emitting isotopes has eliminated large leukemic burdens while minimizing radiation exposure to normal tissues in both nonmyeloablative and myeloablative regimens. Targeted beta-particle immunotherapy with agents such as bismuth 213-labeled HuM195 offers the possibility of a more selective tumor cell kill with less damage to surrounding normal cells. Directed chemotherapy using the anti-CD33-calicheamicin conjugate gemtuzumab ozogamicin (Mylotarg) has produced remissions in patients with relapsed AML.[1]References
- Antibody therapy in acute myeloid leukemia: current status and future directions. Burke, J.M., Jurcic, J.G. Clinical lymphoma. (2002) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
